Olanzapine May Raise Liver Enzymes

Higher doses drive the risk, while valproate may protect

STUDY: Wang F et al, Drug Design, Development and Therapy 2026

STUDY TYPE: Retrospective multicenter cohort study

FUNDING: National Administration of Traditional Chinese Medicine; Hubei Provincial Administration of Traditional Chinese Medicine; Chinese Pharmaceutical Association

Background

Many antipsychotics can raise liver enzymes, including a recent signal on quetiapine. For olanzapine, there are reports in schizophrenia, and this is the first real-world data in bipolar disorder.

The Study

• 487 hospitalized adults with bipolar disorder treated with olanzapine at three hospitals in China.
• Liver function tests drawn at baseline and during treatment; hepatotoxicity defined as any elevation above the upper limit of normal.
• Multivariate logistic regression used to identify independent risk factors.

Results

Nearly 1 in 4 patients (24.2%) developed liver enzyme elevations on olanzapine. Most cases were mild (79.7%), with moderate injury in 11% and severe injury in 9.3%. Onset was fast: the median time to abnormal labs was 13 days.

Higher daily dose was the strongest independent risk factor (odds ratio of 1.07 for each mg increase). Elevated baseline gamma-glutamyl transferase (GGT) also predicted liver injury. GGT rose earlier and more steeply than alanine aminotransferase (ALT) in affected patients, making it the more sensitive early marker.

Surprisingly, patients on concurrent valproate had 45% lower odds of liver injury. Although this anticonvulsant has liver risks of its own, it also lowers peak olanzapine blood levels by competing for protein binding and inhibiting its metabolism, thereby reducing hepatic exposure.

The overall recovery rate was 88% with drug discontinuation or hepatoprotective agents.

Limitations

Association; not causation. Retrospective design with 49% of patients excluded for incomplete labs, introducing selection bias. Hepatotoxicity defined broadly (any elevation above normal), which overcounts clinically significant injury. Chinese inpatient population limits generalizability.

Practice Implications

1. A dose-dependent relationship supports the causation here.
2. If you believe this is causation, you’ll want to monitor liver enzymes on olanzapine (and quetiapine).
3. If you don’t believe there is causation, it’s still a good idea. Over 20% of patients with bipolar and schizophrenia have fatty liver disease.